Glutamate transporter 1-mediated antidepressant-like effect in a rat model of chronic unpredictable stress

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 34, Issue 6, 2014, Pages 838-844

  Chen, Jian xin ^a   Yao, Li hua ^a   Xu, Bi bo ^b   Qian, Kun ^c   Wang, Hui ling ^a   Liu, Zhong chun ^a   Wang, Xiao ping ^a   Wang, Gao hua ^a  

^a WUHAN UNIVERSITY   (China)

^b HUBEI UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

chronic unpredictable stress; fluoxetine; glutamate; glutamate transporter 1; hippocampus

Indexed keywords

ANTIDEPRESSANT AGENT; EXCITATORY AMINO ACID TRANSPORTER 2; FLUOXETINE; SLC1A2 PROTEIN, RAT;

ANIMAL; ANIMAL BEHAVIOR; BRAIN; CHRONIC DISEASE; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; HUMAN; MALE; MENTAL STRESS; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; BRAIN; CHRONIC DISEASE; DEPRESSIVE DISORDER, MAJOR; EXCITATORY AMINO ACID TRANSPORTER 2; FLUOXETINE; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; STRESS, PSYCHOLOGICAL;

EID: 84914177632     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-014-1362-5     Document Type: Article

References (39)

1. Licinio J, Wong ML. Advances in depression research: 2011. Mol Psychiatry, 2011, 16(7):686–687
2. Doris A, Ebmeier K, Shajahan P. Depressive illness. Lancet, 1999, 354(9187):1369–1375
3. Millan MJ. The role of monoamines in the actions of established and “novel” agents: a critical review. Eur J Pharmacol, 2004, 500(1–3):371–384
4. Tokita K, Yamaji T, Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav, 2012, 100(4): 688–704
5. Sanacora G, Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry, 2013, 73(12): 1172–1179
6. Lehre KP, levy LM, Ottersen OP, et al. Differential expression of two glial glutamate transporters in the rats brain: quantitative and immunocyochemical observations. J Neurosci, 1995, 15(3 pt 1):1835–1853
7. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets, 2007, 6(3):219–233
8. Choudary PV, Molnar M, Evans SJ, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA, 2005, 102(43):15 653–15 658
9. Reagan LP, Rosell DR, Wood GE, et al. Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: Reversal by tianeptine. Proc Natl Acad Sci USA, 2004, 101(7):2179–2184
10. Wood GE, Young LT, Reagan LP, et al. Stress-induced structural remodeling in hippocampus: Prevention by lithium treatment. Proc Natl Acad Sci USA, 2004, 101(11): 3973–3978
11. Zink M, Vollmayr B, Gebicke-Haerter PJ, et al. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology, 2010, 58(2):465–473
12. Zink M, Rapp S, Donev R, et al. Fluoxetine treatment induces EAAT2 expression in rat brain. J Neural Transm, 2011, 118(6):849–855
13. Banasr M, Valentine GW, Li XY, et al. Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol Psychiatry, 2007, 62(5):496–504
14. Ye Y, Wang G, Wang H, et al. Brain-derived neurotrophic factor (BDNF) infusion restored astrocytic plasticity in the hippocampus of a rat model of depression. Neurosci Lett, 2011, 503(1):15–19
15. Grippo AJ, Beltz TG, Weiss RM, et al. The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia. Biol Psychiatry, 2006, 59(4):309–316
16. Surget A, Saxe M, Leman S, et al. Drug dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry, 2008, 64(4):293–301
17. Yang C, Wang G, Wang H, et al. Cytoskeletal alterations in rat hippocampus following chronic unpredictable mild stress and re-exposure to acute and chronic unpredictable mild stress. Behav Brain Res, 2009, 205(2):518–524
18. Li Y, Wang H, Wang X, et al. Differential expression of hippocampal EphA4 and ephrinA3 in anhedonic-like behavior, stress resilience, and antidepressant drug treatment after chronic unpredicted mild stress. Neurosci Lett, 2014, 566(30):292–297
19. Kanai Y, Hediger MA. The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects. Pflugers Arc, 2004, 447(5):469–479
20. Beart PM, O’Shea RD. Transporters for L-glutamate: An update on their molecular pharmacology and pathological involvement. Br J Pharmacol, 2007, 150(1):5–17
21. Carbone M, Duty S, Rattray M. Riluzole elevates GLT-1 activity and levels in striatal astrocytes. Neurochem Int, 2012, 60(1):31–38
22. Zarate CA Jr, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry, 2004, 161(1):171–174
23. Zarate CA Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry, 2005, 57(4):430–432
24. Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry, 2007, 61(6):822–825
25. Miller TM, Cleveland DW. Medicine. Treating neurodegenerative diseases with antibiotics. Science, 2005, 307(5708):361–362
26. Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005, 433(7021):73–77
27. Mineur YS, Picciotto MR, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry, 2007, 61(2):250–252
28. Raudensky J, Yamamoto BK. Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function. Brain Res, 2007, 1135(1):129–135
29. Banasr M, Duman RS. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry, 2008, 64(10):863–870
30. Banasr M, Chowdhury GM, Terwilliger R, et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry, 2010, 15(5):501–511
31. Czeh B, Simon M, Schmelting B, et al. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology, 2006, 31(8):1616–1626
32. Hughes EG, Maguire JL, McMinn MT, et al. Loss of glial fibrillary acidic protein results in decreased glutamate transport and inhibition of PKA-induced EAAT2 cell surface trafficking. Brain Res Mol Brain Res, 2004, 124(2): 114–123
33. Mao QX, Yang TD. Amitriptyline upregulates EAAT1 and EAAT2 in neuropathic pain rats. Brain Res Bull, 2010, 81(4–5):424–427
34. McEwen BS, Chattarji S, Diamond DM, et al. The neurobiological properties of Tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry, 2010, 15(3):237–249
35. Thome J, Sakai N, Shin K, et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci, 2000, 20(11):4030–4036
36. Danbolt NC. Glutamate uptake. Prog Neurobiol, 2001, 65(1):1–105
37. Lee Y, Gaskins D, Anand A, et al. Glia mechanisms in mood regulation: a novel model of mood disorders. Psychopharmacology, 2007, 191(1):55–65
38. Bechtholt-Gompf AJ, Walther HV, Adams MA, et al. Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory. Neuropsychopharmacology, 2010, 35(10):2049–2059
39. John CS, Smith KL, Van’t Veer A, et al. Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. Neuropsychopharmacology, 2012, 37(11):2467–2475